Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis

Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis

Background: Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) suffer substantial morbidity and mortality. The meaningful preservation of functional capacity and quality of life are important priorities. Objectives: The 6-minute walk test (6MWT), a measure of functional capacity,...

Full description

Saved in:
Bibliographic Details
Main Authors: John L. Berk, MD, Olivier Lairez, MD, PhD, Pedro Schwartzmann, MD, PhD, Shaun Bender, PhD, Matthew T. White, PhD, Patrick Y. Jay, MD, PhD, David Danese, MBA, Ronald Witteles, MD
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JACC: Advances
Subjects:
ATTR amyloidosis
cardiomyopathy
functional capacity
heart failure
RNAi therapeutics
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X25002960
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items